Surprisingly, despite the encouraging tumor suppressive effects of TGF-β-targeted compounds in vitro and in vivo, their antitumor efficacy in oncology patients is mainly controversial with a small survival benefit [121]. This evidence concerns the gene TGFB1 and neoplasm.